277 / 320
681
Humana Press, 2004, 1-441.
39. Au Yeung S., Ensom M. Phenytoin and Enteral Feedings:
Does Evidence Support an Interaction?. Ann Pharmacother.
2000;34(7-8):896-905.
40. Von Winckelmann S., Spriet I., Willems L. Therapeutic
Drug Monitoring of Phenytoin in Critically Ill Patients.
Pharmacotherapy 2008; 28 (11): 1391-1400.
41. Guldiken B., Rémi J., Noachtar S. Cardiovascular
adverse effects of phenytoin. J Neurol 2016 ;263 (5):861-70.
42. Giaconna N, Bauman JL, Siepler JK: Crystallization of three
phenytoin preparations in intravenous solutions. Am J Hosp
Pharm: 1982. 39: 630-4.
43. Toublanc N., Du X., Liu Y., et al. Pharmacokinetics, Safety and
Bioequivalence of Levetiracetam Intravenous Infusion and
Oral Tablets in Healthy Chinese Subjects. Clin Drug Investig.
(2015) 35: 495-503.
44. Yamamoto J., Toublanc N., Kumagai J., Stockis A.
Levetiracetam Pharmacokinetics in Japanese Subjects with
Renal Impairment. Clin Drug Investig (2014) 34:819–828.
45. Chau K., Yong J., Ismail K., Griffith N., Liu M., Makris A.
Levetiracetam-induced
severe
acute
granulomatous
interstitial nephritis. Clin Kidney J (2012) 5 (3): 234-236.
46. Mahta A., Kim R. Y., Kesari S. Levetiracetam-induced
interstitial nephritis in a patient with glioma. J Clin Neurosci.
2012 Jan;19(1):177-8.
47. Beyreuther B., Freitag J., Heers C., Krebsfänger N.,
Scharfenecker U., Stöhr T. Lacosamide: A Review of Preclinical
Properties. CNS Drug Reviews. 2007, Vol. 13, N 1, pp. 21–42.
48. Cawello W. Clinical pharmacokinetic and pharmacodynamic
profile
of
lacosamide.
Clin
Pharmacokinet.
2015
Sep;54(9):901-14
49. Legros B., Depondt C., Levy-Nogueira M. Intravenous
lacosamide in refractory seizure clusters and status
epilepticus: comparison of 200 and 400 mg loading doses.
Neurocrit Care. 2014;20(3):484-8.
50. Ramsay R.E., Sabharwal V., Khan F. Safety & pK of IV loading
dose of lacosamide in the ICU. Epilepsy Behav. 2015
Aug;49:340-2.
51. Morales E.Y., Peleteiro M., Peña E.C. Observational study of
intravenous lacosamide in patients with convulsive versus
non-convulsive status epilepticus. Clin Drug Investig. 2015
Jul;35(7):463-9.
[FARMACOLOGÍA EN EL PACIENTE NEUROCRÍTICO, FOCO EN LA TERAPIA ANTICONVULSIVANTE - Q.F. Milka Darlic y col.]